MedTrace Logo

A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy Participants

NCT06411860 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2025-10-27

No results posted yet for this study

Summary

The primary objective of the study is:

• To assess the effects of a single therapeutic and supratherapeutic dose of olpasiran on the placebo-corrected change from baseline in QT corrected for heart rate (ΔΔQT)/QTc interval in healthy participants.

Conditions

  • Basic Science

Interventions

OTHER

Placebo

Participants will receive a subcutaneous (SC) injection of placebo.

DRUG

Olpasiran

Participants will receive a SC injection of olpasiran at dose level 1 or 2.

DRUG

Moxifloxacin

Participants will receive a single dose of moxifloxacin as an oral tablet by mouth.

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-09-12
Primary Completion
2024-11-29
Completion
2024-12-11
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06411860 on ClinicalTrials.gov